Page 12 - Brain Dysfunction News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(0) INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) and Incyte (INCY) on Thursday said their late-stage study of baricitinib in hospitalized Covid-19 patients did not achieve the main goal. The phase III study dubbed Cov-Barrier of baricitinib plus standard of care (SoC) versus placebo plus SoC did not meet statistical significance on the primary endpoint. The main goal was defined as the difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membra...

Share this article Share this article INDIANAPOLIS, April 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membrane oxygenat...

Akili Akili, which made history last summer by earning regulatory clearance for the first video-game based therapy, now plans to test if its software can help adults suffering from Covid “brain fog.” Two randomized remote studies, one conducted by Weill Cornell Medicine and New York-Presbyterian Hospital and the other by Vanderbilt University Medical Center, will assess whether AKL-T01, the treatment that Akili commercially markets for ADHD as EndeavorRx, can help improve cognition symptoms in Covid survivors. The new studies come at a pivotal moment for Akili. EndeavorRx is being prescri...

The human side of healing: How seeing loved ones helps COVID-19 patients COVID-19 restrictions are keeping many patients isolated in the hospital, but a new study is highlighting what doctors, patients and families have seen: being near loved ones can play a role in healing — specifically around a common brain dysfunction that comes with COVID-19. Social Sharing Lancet study on 2,088 patients showed family visitation linked to less delirium, a common risk of COVID-19 Posted: Feb 26, 2021 4:00 AM ET | Last Updated: March 1 Tom and Virginia Stevens of Nashville, Tenn., with Dr. Wes Ely. The c...

Vanderbilt University Medical Center Wesley Ely, MD, MPH, co-director of the Critical Illness, Brain Dysfunction, and Survivorship Center at VUMC and senior author. Newswise — Delirium, a form of acute brain dysfunction, is widespread in critically ill patients in lower resourced hospitals, and the duration of delirium predicted both mortality and disability at six months after discharge, according to a study published in PLOS ONE.  Working with partners in Zambia, Vanderbilt University Medical Center researchers evaluated 711 hospitalized critically ill patients; delirium occurred in 48....